Seek Returns logo

LIN vs. LLY: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at LIN and LLY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolLINLLY
Company NameLinde plcEli Lilly and Company
CountryUnited KingdomUnited States
GICS SectorMaterialsHealth Care
GICS IndustryChemicalsPharmaceuticals
Market Capitalization223.03 billion USD592.10 billion USD
ExchangeNasdaqGSNYSE
Listing DateJune 17, 1992June 1, 1972
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of LIN and LLY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

LIN vs. LLY: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolLINLLY
5-Day Price Return1.32%3.06%
13-Week Price Return4.67%-12.58%
26-Week Price Return3.25%-24.11%
52-Week Price Return6.46%-25.32%
Month-to-Date Return3.34%-10.75%
Year-to-Date Return13.61%-14.44%
10-Day Avg. Volume1.53M8.71M
3-Month Avg. Volume1.91M4.45M
3-Month Volatility13.61%41.63%
Beta0.960.45

Profitability

Return on Equity (TTM)

LIN

17.46%

Chemicals Industry

Max
26.17%
Q3
13.48%
Median
8.13%
Q1
2.52%
Min
-11.86%

In the upper quartile for the Chemicals industry, LIN’s Return on Equity of 17.46% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

LLY

88.36%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

LLY’s Return on Equity of 88.36% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

LIN vs. LLY: A comparison of their Return on Equity (TTM) against their respective Chemicals and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

LIN

20.20%

Chemicals Industry

Max
21.80%
Q3
9.57%
Median
4.44%
Q1
1.14%
Min
-11.30%

A Net Profit Margin of 20.20% places LIN in the upper quartile for the Chemicals industry, signifying strong profitability and more effective cost management than most of its peers.

LLY

25.91%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

A Net Profit Margin of 25.91% places LLY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

LIN vs. LLY: A comparison of their Net Profit Margin (TTM) against their respective Chemicals and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

LIN

26.75%

Chemicals Industry

Max
27.33%
Q3
13.97%
Median
8.08%
Q1
4.46%
Min
-8.10%

An Operating Profit Margin of 26.75% places LIN in the upper quartile for the Chemicals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

LLY

32.37%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

An Operating Profit Margin of 32.37% places LLY in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

LIN vs. LLY: A comparison of their Operating Profit Margin (TTM) against their respective Chemicals and Pharmaceuticals industry benchmarks.

Profitability at a Glance

SymbolLINLLY
Return on Equity (TTM)17.46%88.36%
Return on Assets (TTM)8.10%16.02%
Net Profit Margin (TTM)20.20%25.91%
Operating Profit Margin (TTM)26.75%32.37%
Gross Profit Margin (TTM)48.45%82.64%

Financial Strength

Current Ratio (MRQ)

LIN

0.93

Chemicals Industry

Max
3.38
Q3
2.23
Median
1.73
Q1
1.39
Min
0.55

LIN’s Current Ratio of 0.93 falls into the lower quartile for the Chemicals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

LLY

1.28

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

LLY’s Current Ratio of 1.28 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.

LIN vs. LLY: A comparison of their Current Ratio (MRQ) against their respective Chemicals and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

LIN

0.67

Chemicals Industry

Max
1.65
Q3
0.94
Median
0.65
Q1
0.41
Min
0.00

LIN’s Debt-to-Equity Ratio of 0.67 is typical for the Chemicals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

LLY

2.18

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

LLY’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 2.18. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

LIN vs. LLY: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Chemicals and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

LIN

33.09

Chemicals Industry

Max
56.43
Q3
26.33
Median
9.38
Q1
3.10
Min
-9.39

LIN’s Interest Coverage Ratio of 33.09 is in the upper quartile for the Chemicals industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

LLY

20.36

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

LLY’s Interest Coverage Ratio of 20.36 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

LIN vs. LLY: A comparison of their Interest Coverage Ratio (TTM) against their respective Chemicals and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

SymbolLINLLY
Current Ratio (MRQ)0.931.28
Quick Ratio (MRQ)0.700.53
Debt-to-Equity Ratio (MRQ)0.672.18
Interest Coverage Ratio (TTM)33.0920.36

Growth

Revenue Growth

LIN vs. LLY: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

LIN vs. LLY: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

LIN

1.23%

Chemicals Industry

Max
6.56%
Q3
4.04%
Median
2.47%
Q1
1.45%
Min
0.00%

LIN’s Dividend Yield of 1.23% is in the lower quartile for the Chemicals industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.

LLY

0.82%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

LLY’s Dividend Yield of 0.82% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

LIN vs. LLY: A comparison of their Dividend Yield (TTM) against their respective Chemicals and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

LIN

40.71%

Chemicals Industry

Max
181.25%
Q3
95.01%
Median
53.52%
Q1
26.59%
Min
0.00%

LIN’s Dividend Payout Ratio of 40.71% is within the typical range for the Chemicals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

LLY

36.46%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

LLY’s Dividend Payout Ratio of 36.46% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

LIN vs. LLY: A comparison of their Dividend Payout Ratio (TTM) against their respective Chemicals and Pharmaceuticals industry benchmarks.

Dividend at a Glance

SymbolLINLLY
Dividend Yield (TTM)1.23%0.82%
Dividend Payout Ratio (TTM)40.71%36.46%

Valuation

Price-to-Earnings Ratio (TTM)

LIN

33.22

Chemicals Industry

Max
42.94
Q3
29.77
Median
20.37
Q1
14.27
Min
6.19

A P/E Ratio of 33.22 places LIN in the upper quartile for the Chemicals industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

LLY

44.55

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

At 44.55, LLY’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

LIN vs. LLY: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Chemicals and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

LIN

6.71

Chemicals Industry

Max
4.36
Q3
2.23
Median
1.01
Q1
0.55
Min
0.16

With a P/S Ratio of 6.71, LIN trades at a valuation that eclipses even the highest in the Chemicals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

LLY

11.54

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

With a P/S Ratio of 11.54, LLY trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

LIN vs. LLY: A comparison of their Price-to-Sales Ratio (TTM) against their respective Chemicals and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

LIN

5.73

Chemicals Industry

Max
4.92
Q3
2.56
Median
1.54
Q1
0.97
Min
0.30

At 5.73, LIN’s P/B Ratio is at an extreme premium to the Chemicals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

LLY

40.43

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

At 40.43, LLY’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

LIN vs. LLY: A comparison of their Price-to-Book Ratio (MRQ) against their respective Chemicals and Pharmaceuticals industry benchmarks.

Valuation at a Glance

SymbolLINLLY
Price-to-Earnings Ratio (TTM)33.2244.55
Price-to-Sales Ratio (TTM)6.7111.54
Price-to-Book Ratio (MRQ)5.7340.43
Price-to-Free Cash Flow Ratio (TTM)44.00305.94